Journal
EMBO MOLECULAR MEDICINE
Volume 10, Issue 4, Pages -Publisher
WILEY
DOI: 10.15252/emmm.201708689
Keywords
directly bind; inflammasome-driven diseases; inhibitor; NLRP3; tranilast
Categories
Funding
- National Basic Research Program of China [2014CB910800]
- Fundamental Research Funds for the Central Universities
- Strategic Priority Research Program of the Chinese Academy of Sciences [XDA12040310, XDPB0303]
- National Natural Science Foundation of China [81701549, 91742202, 81722022, 81788101, 31700777, 81525013]
- Young Talent Support Program
Ask authors/readers for more resources
The dysregulation of NLRP3 inflammasome can cause uncontrolled inflammation and drive the development of a wide variety of human diseases, but the medications targeting NLRP3 inflammasome are not available in clinic. Here, we show that tranilast (TR), an old anti-allergic clinical drug, is a direct NLRP3 inhibitor. TR inhibits NLRP3 inflammasome activation in macrophages, but has no effects on AIM2 or NLRC4 inflammasome activation. Mechanismly, TR directly binds to the NACHT domain of NLRP3 and suppresses the assembly of NLRP3 inflammasome by blocking NLRP3 oligomerization. In vivo experiments show that TR has remarkable preventive or therapeutic effects on the mouse models of NLRP3 inflammasome-related human diseases, including gouty arthritis, cryopyrin-associated autoinflammatory syndromes, and type 2 diabetes. Furthermore, TR is active exvivo for synovial fluid mononuclear cells from patients with gout. Thus, our study identifies the old drug TR as a direct NLRP3 inhibitor and provides a potentially practical pharmacological approach for treating NLRP3-driven diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available